Skip to Main Content

6,927

Views

83

CrossRef citations to date

0

Altmetric

Original Articles

Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: the DASFREE study

Neil P. ShahDepartment of Medicine/Hematology-Oncology, UCSF School of Medicine, San Francisco, CA, USA; Correspondence[email protected]
View further author information

,

Valentín García-GutiérrezServicio Hematología y Hemoterapia, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain; View further author information

,

Antonio Jiménez-VelascoHospital Universitario Carlos Haya, Malaga, Spain; View further author information

,

Sarah LarsonDavid Geffen School of Medicine at UCLA, Los Angeles, CA, USA; View further author information

,

Susanne SausseleIII, Med. Clinic, Medizinische Fakultät Mannheim der Universität Heidelberg, Mannheim, Germany; View further author information

,

Delphine ReaDepartment of Hématologie, Hôpital Saint-Louis, Paris, France; View further author information

,

François-Xavier MahonDepartment of Hématologie, Institut Bergonié, University of Bordeaux, Bordeaux, France; View further author information

,

Moshe Yair LevyBaylor Charles A. Sammons Cancer Center, Dallas, TX, USA; View further author information

,

María Teresa Gómez-CasaresHospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain; View further author information

,

Fabrizio PaneDipartimento di Medicina clinica e Chirurgia, Università degli Studi di Napoli Federico II, Naples, Italy; View further author information

,

Franck-Emmanuel NicoliniHématologie Clinique, Centre Léon Bérard, Lyon, France; View further author information

,

Michael J. MauroMyeloproliferative Neoplasms Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; View further author information

,

Oumar SyBristol-Myers Squibb, Princeton, NJ, USA; View further author information

,

Patricia Martin-RegueiraBristol-Myers Squibb, Princeton, NJ, USA; View further author information

&

Jeffrey H. LiptonDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, CanadaView further author information